Acceleron to Present at the 21st Annual Future Leaders in the Biotech Industry Conference

Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--

Acceleron Pharma Inc. (XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases, today announced its participation at the 21st Annual Future Leaders in the Biotech Industry Conference to be held on March 28, 2014 at the Millennium Broadway Hotel & Conference Center in New York City.

 
Acceleron Speaker:       John Knopf, Ph.D., Chief Executive Officer of Acceleron
Date: March 28, 2014
Time: 11:30 AM (EDT)
Location: Room 402/403, Millennium Broadway Hotel & Conference Center
 

A live audio webcast of the presentation will be available on the “Events and Presentations” page in the Investors & Media section on the Company’s website (http://investor.acceleronpharma.com/events.cfm).

A replay of the webcast will be available from Acceleron’s website for thirty days after the conference.

About Acceleron

Acceleron is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases. The company is a leader in understanding the biology of the Transforming Growth Factor-Beta (TGF-β) protein superfamily, a large and diverse group of molecules that are key regulators in the growth and repair of tissues throughout the human body, and in targeting these pathways to develop important new medicines. Acceleron has built a highly productive R&D platform that has generated innovative clinical and preclinical protein therapeutic candidates with novel mechanisms of action. These protein therapeutic candidates have the potential to significantly improve clinical outcomes for patients with cancer and rare diseases.

For more information, please visit www.acceleronpharma.com.

Contact:
Acceleron Pharma
Kevin F. McLaughlin, 617-649-9204
Senior Vice President and Chief Financial Officer
or
Media:
Suda Communications LLC
Maureen L. Suda, 585-387-9248

Rates

View Comments (0)